Directed evolution generates a novel oncolytic virus for the treatment of colon cancer.
<h4>Background</h4>Viral-mediated oncolysis is a novel cancer therapeutic approach with the potential to be more effective and less toxic than current therapies due to the agents selective growth and amplification in tumor cells. To date, these agents have been highly safe in patients bu...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/791544878a6041298c0ab175a5f83c9b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:791544878a6041298c0ab175a5f83c9b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:791544878a6041298c0ab175a5f83c9b2021-11-25T06:12:01ZDirected evolution generates a novel oncolytic virus for the treatment of colon cancer.1932-620310.1371/journal.pone.0002409https://doaj.org/article/791544878a6041298c0ab175a5f83c9b2008-06-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18560559/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Viral-mediated oncolysis is a novel cancer therapeutic approach with the potential to be more effective and less toxic than current therapies due to the agents selective growth and amplification in tumor cells. To date, these agents have been highly safe in patients but have generally fallen short of their expected therapeutic value as monotherapies. Consequently, new approaches to generating highly potent oncolytic viruses are needed. To address this need, we developed a new method that we term "Directed Evolution" for creating highly potent oncolytic viruses.<h4>Methodology/principal findings</h4>Taking the "Directed Evolution" approach, viral diversity was increased by pooling an array of serotypes, then passaging the pools under conditions that invite recombination between serotypes. These highly diverse viral pools were then placed under stringent directed selection to generate and identify highly potent agents. ColoAd1, a complex Ad3/Ad11p chimeric virus, was the initial oncolytic virus derived by this novel methodology. ColoAd1, the first described non-Ad5-based oncolytic Ad, is 2-3 logs more potent and selective than the parent serotypes or the most clinically advanced oncolytic Ad, ONYX-015, in vitro. ColoAd1's efficacy was further tested in vivo in a colon cancer liver metastasis xenograft model following intravenous injection and its ex vivo selectivity was demonstrated on surgically-derived human colorectal tumor tissues. Lastly, we demonstrated the ability to arm ColoAd1 with an exogenous gene establishing the potential to impact the treatment of cancer on multiple levels from a single agent.<h4>Conclusions/significance</h4>Using the "Directed Evolution" methodology, we have generated ColoAd1, a novel chimeric oncolytic virus. In vitro, this virus demonstrated a >2 log increase in both potency and selectivity when compared to ONYX-015 on colon cancer cells. These results were further supported by in vivo and ex vivo studies. Furthermore, these results have validated this methodology as a new general approach for deriving clinically-relevant, highly potent anti-cancer virotherapies.Irene KuhnPaul HardenMaxine BauzonCecile ChartierJulie NyeSteve ThorneTony ReidShaoheng NiAndre LieberKerry FisherLen SeymourGabor M RubanyiRichard N HarkinsTerry W HermistonPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 3, Iss 6, p e2409 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Irene Kuhn Paul Harden Maxine Bauzon Cecile Chartier Julie Nye Steve Thorne Tony Reid Shaoheng Ni Andre Lieber Kerry Fisher Len Seymour Gabor M Rubanyi Richard N Harkins Terry W Hermiston Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. |
| description |
<h4>Background</h4>Viral-mediated oncolysis is a novel cancer therapeutic approach with the potential to be more effective and less toxic than current therapies due to the agents selective growth and amplification in tumor cells. To date, these agents have been highly safe in patients but have generally fallen short of their expected therapeutic value as monotherapies. Consequently, new approaches to generating highly potent oncolytic viruses are needed. To address this need, we developed a new method that we term "Directed Evolution" for creating highly potent oncolytic viruses.<h4>Methodology/principal findings</h4>Taking the "Directed Evolution" approach, viral diversity was increased by pooling an array of serotypes, then passaging the pools under conditions that invite recombination between serotypes. These highly diverse viral pools were then placed under stringent directed selection to generate and identify highly potent agents. ColoAd1, a complex Ad3/Ad11p chimeric virus, was the initial oncolytic virus derived by this novel methodology. ColoAd1, the first described non-Ad5-based oncolytic Ad, is 2-3 logs more potent and selective than the parent serotypes or the most clinically advanced oncolytic Ad, ONYX-015, in vitro. ColoAd1's efficacy was further tested in vivo in a colon cancer liver metastasis xenograft model following intravenous injection and its ex vivo selectivity was demonstrated on surgically-derived human colorectal tumor tissues. Lastly, we demonstrated the ability to arm ColoAd1 with an exogenous gene establishing the potential to impact the treatment of cancer on multiple levels from a single agent.<h4>Conclusions/significance</h4>Using the "Directed Evolution" methodology, we have generated ColoAd1, a novel chimeric oncolytic virus. In vitro, this virus demonstrated a >2 log increase in both potency and selectivity when compared to ONYX-015 on colon cancer cells. These results were further supported by in vivo and ex vivo studies. Furthermore, these results have validated this methodology as a new general approach for deriving clinically-relevant, highly potent anti-cancer virotherapies. |
| format |
article |
| author |
Irene Kuhn Paul Harden Maxine Bauzon Cecile Chartier Julie Nye Steve Thorne Tony Reid Shaoheng Ni Andre Lieber Kerry Fisher Len Seymour Gabor M Rubanyi Richard N Harkins Terry W Hermiston |
| author_facet |
Irene Kuhn Paul Harden Maxine Bauzon Cecile Chartier Julie Nye Steve Thorne Tony Reid Shaoheng Ni Andre Lieber Kerry Fisher Len Seymour Gabor M Rubanyi Richard N Harkins Terry W Hermiston |
| author_sort |
Irene Kuhn |
| title |
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. |
| title_short |
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. |
| title_full |
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. |
| title_fullStr |
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. |
| title_full_unstemmed |
Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. |
| title_sort |
directed evolution generates a novel oncolytic virus for the treatment of colon cancer. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2008 |
| url |
https://doaj.org/article/791544878a6041298c0ab175a5f83c9b |
| work_keys_str_mv |
AT irenekuhn directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT paulharden directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT maxinebauzon directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT cecilechartier directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT julienye directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT stevethorne directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT tonyreid directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT shaohengni directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT andrelieber directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT kerryfisher directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT lenseymour directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT gabormrubanyi directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT richardnharkins directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer AT terrywhermiston directedevolutiongeneratesanoveloncolyticvirusforthetreatmentofcoloncancer |
| _version_ |
1718414050020294656 |